Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVXGet Free Report) COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at approximately $17,735,022.90. This represents a 3.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jim Wassil also recently made the following trade(s):

  • On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00.
  • On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00.

Vaxcyte Price Performance

PCVX opened at $86.51 on Wednesday. The stock’s 50 day moving average price is $87.46 and its 200-day moving average price is $94.42. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVXGet Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the company earned ($0.91) EPS. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently modified their holdings of the stock. Riverview Trust Co bought a new stake in Vaxcyte during the 3rd quarter valued at approximately $27,000. Blue Trust Inc. boosted its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares in the last quarter. Meeder Asset Management Inc. grew its stake in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after purchasing an additional 635 shares during the period. Nomura Asset Management Co. Ltd. bought a new position in Vaxcyte in the third quarter worth $92,000. Finally, Signaturefd LLC lifted its position in Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after buying an additional 358 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on PCVX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and an average target price of $145.71.

Check Out Our Latest Stock Analysis on PCVX

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Read More

Insider Buying and Selling by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.